Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
33SzA8ssLHb324ZP
